drugset / Trial / NCT02148796

Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness

NCT02148796 ↗

Phase 2 Completed 822 enrolled University of Arizona
RandomizedParallel-groupTriple-blindPrevention

Summary

The primary objective of this study is to evaluate if Broncho-Vaxom® given to high risk infants for 10 days, monthly, for two consecutive years can increase time to occurrence of the first episode of wheezing lower respiratory tract illness (WLRI) during a three year observation period off therapy.

Timeline

Start
2017-01-01
Primary completion
2026-01-30
Completion
2026-01-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Broncho-Vaxom (BV) Other / unclassified 3.5 mg Oral

Indications